🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06755866
Recruiting Not applicable

DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer

NCT06755866 · tracked via the Priya Life Science China tracker
Sponsor
Yunnan Cancer Hospital
Phase
Not applicable
Started
2024-11-26
Last updated
2025-01-01

Condition(s) studied

Esophageal Cancer

Investigational drug(s) / intervention(s)

The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer

The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer: Chest MRI scan outside of standard treatment options

Study summary

To prospectively collect medical images and clinical data related to esophageal cancer using 4D Free Breathing DCE-MRI technology, to evaluate the image quality in the diagnosis of esophageal cancer, and to predict the efficacy of preoperative neoadjuvant chemoradiotherapy for esophageal cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Be 18 years of age and older; 2. First diagnosis of esophageal squamous cell carcinoma confirmed by histopathological biopsy; 3. The clinical stage is cT1b\~cT2N+; or the clinical stage is cT3\~cT4 any N, (thoracic esophageal cancer, esophagogastric junction cancer); 4. There are no contraindications to MRI examination Exclusion Criteria: 1. Have other primary tumors; 2. The image quality does not meet the diagnostic criteria; 3. Those who do not cooperate with the inspection; 4. Patients who have received prior chemoradiotherapy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Yunnan Cancer Hospital Kunming Yunnan Recruiting

More Yunnan Cancer Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06755866 on ClinicalTrials.gov ↗ ← All trials in China